Märkl, Florian http://orcid.org/0000-0003-4285-0380
Schultheiß, Christoph http://orcid.org/0000-0001-9789-5776
Ali, Murtaza
Chen, Shih-Shih
Zintchenko, Marina
Egli, Lukas
Mietz, Juliane http://orcid.org/0009-0007-9359-2242
Chijioke, Obinna http://orcid.org/0000-0003-4247-5947
Paschold, Lisa http://orcid.org/0000-0003-0020-1315
Spajic, Sebastijan
Holtermann, Anne
Dörr, Janina http://orcid.org/0000-0001-9447-882X
Stock, Sophia
Zingg, Andreas
Läubli, Heinz http://orcid.org/0000-0002-8910-5620
Piseddu, Ignazio
Anz, David
Minden, Marcus Dühren-von
Zhang, Tianjiao
Nerreter, Thomas http://orcid.org/0000-0002-0493-1369
Hudecek, Michael http://orcid.org/0000-0002-2280-2202
Minguet, Susana http://orcid.org/0000-0001-8211-5538
Chiorazzi, Nicholas http://orcid.org/0000-0003-1023-6650
Kobold, Sebastian http://orcid.org/0000-0002-5612-4673
Binder, Mascha http://orcid.org/0000-0003-0663-3004
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (BI 1711/4-1)
Article History
Received: 5 December 2023
Accepted: 22 January 2024
First Online: 2 February 2024
Competing interests
: M.D.M. discloses to be shareholder of AVA-Lifescience GmbH and inventor of patent application WO/2023/152204 (ANTIBODIES TARGETING THE B-CELL RECEPTOR OF CHRONIC LYMPHOCYTIC LEUKEMIA AND USES THEREOF). The use of the afore mentioned antibody sequences in CAR T cells is subject to the current patent application EP22186810.2 by M.D.M. and M.B. S.K., M.H. and T.N. are inventors of several patents in the field of cellular therapies. S.K. has received honoraria from BMS, GSK, Galapagos, Cymab, Novartis, Miltenyi Biomedicines and TCR2 Inc. S.K. has received license payments from TCR2 Inc and Carina Biotech. S.K. received research support from Arcus Biosciences, Plectonic GmbH, Tabby Therapeutics, Catalym GmbH and TCR2 Inc for work unrelated to this manuscript. All other authors disclose no potential conflicts of interest.